Company / Accounts Receivable
Anika Therapeutics, Inc. Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$23.7M
FY2025
5-year range
$23.6M / $34.6M
FY2021-FY2025
Trend
+0.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable returned to growth in FY2025 after 2 years of decline, reaching $24M.
Based on SEC 10-K filings.
$24M in FY2025 with a 5-year CAGR of +0.5%.
Declined from $26M to $24M over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -11.9%
- 5-Year CAGR
- +0.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +0.5%, indicating consistent growth.
- In FY2025, accounts receivable increased 0.4% year-over-year.
- Peak accounts receivable was recorded in FY2022.
- Lowest accounts receivable in the period was in FY2018.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $23.7M | +0.4% |
| FY2024 | $23.6M | -10.5% |
| FY2023 | $26.4M | -23.9% |
| FY2022 | $34.6M | +16.0% |
| FY2021 | $29.8M | +29.3% |
| FY2020 | $23.1M | +0.0% |
| FY2019 | $23.1M | +11.1% |
| FY2018 | $20.8M | -12.8% |
| FY2017 | $23.8M | -13.7% |
| FY2016 | $27.6M | +27.5% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026